乳腺癌患者激素治疗相关骨病的管理。

Management of bone disease in patients undergoing hormonal therapy for breast cancer.

机构信息

Division of Endocrinology, University of Connecticut Health Center, Farmington, CT 06030, USA.

出版信息

Endocrinol Metab Clin North Am. 2011 Sep;40(3):549-62, viii. doi: 10.1016/j.ecl.2011.05.008.

DOI:10.1016/j.ecl.2011.05.008

Abstract

Estrogen deficiency at menopause is associated with increased risk of bone loss and osteoporosis. Aromatase inhibitors (AIs) are increasingly being used for the treatment of postmenopausal hormone-sensitive breast cancer because of better disease-free survival compared with tamoxifen seen in clinical trials with AIs. This article reviews the effect of endocrine therapies of breast cancer on bone and the management of bone disease with these endocrine therapies. The effect of these therapies on bone mineral density and bone turnover along with possible interventions is discussed. AIs are also associated with skeletal-related events, which are not discussed.

摘要

绝经后雌激素缺乏与骨丢失和骨质疏松症风险增加有关。芳香化酶抑制剂（AIs）在治疗绝经后激素敏感性乳腺癌方面的应用越来越广泛，因为与临床试验中使用他莫昔芬相比，AIs 可获得更好的无病生存。本文综述了乳腺癌内分泌治疗对骨骼的影响以及这些内分泌治疗对骨骼疾病的管理。讨论了这些治疗方法对骨密度和骨转换的影响以及可能的干预措施。AIs 还与骨骼相关事件相关，但本文不做讨论。